Sunday, November 13, 2022
- 9:00AM-10:30AM
-
Abstract Number: 0927
Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
RA – Treatment Poster II- 9:00AM-10:30AM
-
Abstract Number: 0805
Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
Infection-related Rheumatic Disease Poster- 9:00AM-10:30AM
-
Abstract Number: 0756
Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
Immunological Complications of Medical Therapy Poster- 9:00AM-10:30AM
-
Abstract Number: 0891
Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
RA – Diagnosis, Manifestations, and Outcomes Poster II- 9:00AM-10:30AM
-
Abstract Number: 0910
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
RA – Diagnosis, Manifestations, and Outcomes Poster II- 9:00AM-10:30AM
-
Abstract Number: 0623
Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
RA – Etiology and Pathogenesis Poster- 9:00AM-10:30AM
-
Abstract Number: 0737
Rheumatologic Rashes in Different Skin Types and Confidence in Diagnosis Among Internal Medicine Residents in a New York City Hospital
Health Services Research Poster II- 9:00AM-10:30AM
-
Abstract Number: 0710
Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
Epidemiology and Public Health Poster I- 9:00AM-10:30AM
-
Abstract Number: 0898
Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication
RA – Diagnosis, Manifestations, and Outcomes Poster II- 9:00AM-10:30AM
-
Abstract Number: 0723
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
Epidemiology and Public Health Poster I- 9:00AM-10:30AM
-
Abstract Number: 1033
Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort
Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II- 9:00AM-10:30AM
-
Abstract Number: 1049
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Systemic Sclerosis and Related Disorders – Clinical Poster I- 9:00AM-10:30AM
-
Abstract Number: 0720
Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study
Epidemiology and Public Health Poster I- 9:00AM-10:30AM
-
Abstract Number: 0781
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose